Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours

Inclusion Criteria: 1. Signed informed consent form must be obtained prior to any research procedure. 2. Histologically or cytologically confirmed diagnosis of metastatic solid tumours 3. ECOG performance status of 0-3; 4. Adequate organ function defined as: ANC≥1.0×10\^9/L, PLT≥75×10\^9/L, ALB≥25g/L, TBIL≤1.5×ULN, AST≤2.5×ULN, ALT≤2.5×ULN, ALP≤2.5×ULN, Cr≤1.5×ULN; 5. The patient's own PBMCs or PBMCs from a biological parent or child who is willing to donate blood will be used to prepare CAR-NK cells. The parent or child should be ≥18 and ≤60 years old, and he or she is able to sign the informed consent for blood donation by himself/herself; 6. Patients who won't benefit from surgery, or refuse surgical treatment; patients who won't benefit from chemotherapy, can't tolerate chemotherapy or refuse chemotherapy. 7. Patients volunteer to participate in this study and sign the informed consent form for subjects; 8. Blood donors sign the informed consent form for blood donors. 9. Blood donors have negative test results for HIV, HBV and HCV; 10. If a subject or blood donor is a female of childbearing potential, she must have a negative urine pregnancy test result. Exclusion Criteria: 1. Patients who are suffering from uncontrollable or active infectious diseases of the hematological system, cardiovascular system, respiratory system, digestive system, urinary system, or the endocrine system; 2. Patients with immunologic deficiency or autoimmune diseases; 3. Patients with severe hypersensitivity reactions; 4. Patients received other forms of cellular therapies within the last 3 months; 5. Patients received systemic steroids within the last 3 months; 6. Patients who are breastfeeding or pregnant; 7. Patients with brain metastases; 8. Patients who have received an organ transplant.